EMBR-30. A NOVEL PLK1 INHIBITOR ONVANSERTIB EFFECTIVELY SENSITIZES GROUP 3 MEDULLOBLASTOMA TO RADIOTHERAPY
Sign Up to like & getrecommendations! Published in 2021 at "Neuro-oncology"
DOI: 10.1093/neuonc/noab090.047
Abstract: Medulloblastoma (MB) is often accompanied by MYC amplification. PLK1 is an oncogenic kinase that controls cell cycle and proliferation, and it has been preclinically validated as a cancer therapeutic target. Onvansertib (PCM-075) is a novel,… read more here.
Keywords: plk1; plk1 inhibitor; cell; group ... See more keywords
Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
Sign Up to like & getrecommendations! Published in 2019 at "EMBO Molecular Medicine"
DOI: 10.15252/emmm.201809960
Abstract: To address the need for improved systemic therapy for non–small‐cell lung cancer (NSCLC), we previously demonstrated that mesenchymal NSCLC was sensitive to polo‐like kinase (Plk1) inhibitors, but the mechanisms of resistance in epithelial NSCLC remain… read more here.
Keywords: inhibitor induced; induced apoptosis; inhibition; plk1 inhibition ... See more keywords
In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.960720
Abstract: Background Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene CDKN2A has been described as the most frequent genetic alteration in chordomas and may be considered as… read more here.
Keywords: cdk4 inhibitor; plk1 inhibitor; inhibitor; palbociclib ... See more keywords